In a patient with diabetes who has Bell's palsy, how should I dose hydrocortisone, prednisone, or dexamethasone when those are the only steroids available?

Steroid Dosing for Bell's Palsy in Diabetic Patients

Use prednisone 60 mg daily for 5 days followed by a 5-day taper (or prednisolone 50 mg daily for 10 days) within 72 hours of symptom onset, even in diabetic patients, as the benefit of facial nerve recovery outweighs the transient hyperglycemic risk. 1

Recommended Steroid Regimens

The AAO-HNS guideline provides strong evidence-based recommendations for oral corticosteroids in Bell's palsy patients ≥16 years old 1:

Prednisone Option:

• 60 mg daily for 5 days
• Then taper over 5 days (typically 40 mg, 30 mg, 20 mg, 10 mg, 5 mg)
• Total duration: 10 days

Prednisolone Alternative:

• 50 mg daily for 10 days (no taper)
• Or 25 mg twice daily for 10 days

Both regimens demonstrated 83-94% complete recovery rates at 3-9 months in high-quality RCTs, compared to 63-82% with placebo 1.

Hydrocortisone Conversion (If Necessary)

If only hydrocortisone is available, use the conversion ratio where 20 mg hydrocortisone = 5 mg prednisolone 2:

• Equivalent dose: 240 mg hydrocortisone daily for 5 days, then taper
• However, this is not recommended as the evidence base specifically used prednisolone/prednisone, and hydrocortisone requires multiple daily doses due to shorter half-life

Dexamethasone Conversion (If Necessary)

While not specifically studied in Bell's palsy trials, dexamethasone can be converted using standard equivalencies (0.75 mg dexamethasone ≈ 5 mg prednisone):

• Approximate dose: 9 mg dexamethasone daily
• Caution: Dexamethasone causes more pronounced hyperglycemia in diabetics and has longer duration of action 3

Managing Diabetes During Steroid Treatment

Blood Glucose Monitoring

Recent evidence shows steroid-treated diabetic Bell's palsy patients experience modest glucose elevation (mean increase ~10 mg/dL) with small absolute risk of hyperglycemic emergencies 4:

• Monitor glucose closely during treatment
• Expect peak hyperglycemia 4-6 hours after prednisone administration 3, 5
• HbA1c at 1-6 months shows no significant difference 4

Insulin Adjustment Strategy

For diabetic patients on insulin, the ADA guidelines recommend 3:

• Increase prandial and correction insulin by 40-60% when on glucocorticoids
• NPH insulin administered concomitantly with intermediate-acting steroids (prednisone) is standard approach
• Administer NPH in addition to existing basal-bolus regimen
• Daily adjustments based on point-of-care glucose monitoring are critical

Oral Medication Adjustments

For patients on oral agents 6:

• Continue oral medications if fasting glucose <200 mg/dL
• Increase doses as needed
• Consider adding rapid-acting insulin for postprandial coverage if glucose >200 mg/dL

Critical Timing Considerations

Initiate steroids within 72 hours of symptom onset - this is the evidence-based window for maximum benefit 1. The benefit after 72 hours is unclear. Do not delay treatment to optimize glucose control, as the window for facial nerve recovery is time-sensitive.

Risk-Benefit Analysis for Diabetics

The absolute risk increase is minimal 4:

• Hyperosmolar hyperglycemic state (HHS): 1.82% vs 0.57% (NNH = 80)
• Diabetic ketoacidosis (DKA): no significant difference (1.10% vs 0.84%)
• Small transient glucose elevation (~10 mg/dL mean increase)

The substantial benefit of preventing permanent facial paralysis (15-30% risk of incomplete recovery without steroids) far outweighs the small, manageable hyperglycemic risk.

Common Pitfalls to Avoid

1. Do not withhold steroids due to diabetes - the evidence shows manageable glucose effects with monitoring 4
2. Do not use antiviral monotherapy alone - strong recommendation against this approach 1
3. Do not substitute hydrocortisone routinely - stick with prednisone/prednisolone as studied in trials
4. Do not delay beyond 72 hours - efficacy decreases significantly after this window
5. Administer prednisone in the morning (before 9 AM) to minimize HPA axis suppression 5

Additional Considerations

• Eye protection is mandatory for patients with impaired eye closure 1
• Combination antiviral therapy (valacyclovir/acyclovir) may be offered as an option but is not required 1
• Arrange glucose monitoring at discharge with clear instructions for insulin adjustment
• Follow-up at 3 months if incomplete recovery 1